{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T07:53:05Z","timestamp":1784965985841,"version":"3.55.0"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T00:00:00Z","timestamp":1744243200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology - Research and Practice"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.prp.2025.155960","type":"journal-article","created":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T02:00:19Z","timestamp":1744164019000},"page":"155960","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Prognostic impact of combined loss of RB1, p53 and p21 in muscle-invasive bladder cancer"],"prefix":"10.1016","volume":"270","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2126-7305","authenticated-orcid":false,"given":"Benedikt","family":"Ebner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lennert","family":"Eismann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Hermans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Kidess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Pyrgidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Semmler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yannic","family":"Volz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Buchner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Chaloupka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Lisa","family":"Eich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Weinhold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian G.","family":"Stief","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Horst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald B.","family":"Schulz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Schallenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.prp.2025.155960_bib1","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ccr.2014.01.009","article-title":"Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy","volume":"25","author":"Choi","year":"2014","journal-title":"Cancer Cell"},{"issue":"5","key":"10.1016\/j.prp.2025.155960_bib2","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.euf.2023.03.012","article-title":"Intratumoral heterogeneity of molecular subtypes in muscle-invasive bladder cancer-an extensive multiregional immunohistochemical analysis","volume":"9","author":"Schallenberg","year":"2023","journal-title":"Eur. Urol. Focus"},{"issue":"19","key":"10.1016\/j.prp.2025.155960_bib3","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1200\/JCO.2017.75.0158","article-title":"Multicenter prospective phase II trial of neoadjuvant dose-dense gemcitabine plus cisplatin in patients with muscle-invasive bladder cancer","volume":"36","author":"Iyer","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"17","key":"10.1016\/j.prp.2025.155960_bib4","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1200\/JCO.2017.75.7740","article-title":"Alterations in DNA damage response and repair genes as potential marker of clinical benefit from PD-1\/PD-L1 blockade in advanced urothelial cancers","volume":"36","author":"Teo","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.prp.2025.155960_bib5","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s13000-023-01295-y","article-title":"Immunohistochemical based molecular subtypes of muscle-invasive bladder cancer: association with HER2 and EGFR alterations, neoadjuvant chemotherapy response and survival","volume":"18","author":"Helal","year":"2023","journal-title":"Diagn. Pathol."},{"issue":"1","key":"10.1016\/j.prp.2025.155960_bib6","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.eururo.2023.08.016","article-title":"European association of urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2023 guidelines","volume":"85","author":"Alfred Witjes","year":"2024","journal-title":"Eur. Urol."},{"issue":"1","key":"10.1016\/j.prp.2025.155960_bib7","first-page":"2425091","article-title":"Diagnostic and prognostic markers in bladder cancer","volume":"2016","author":"Ku","year":"2016","journal-title":"Dis. Markers"},{"issue":"5","key":"10.1016\/j.prp.2025.155960_bib8","doi-asserted-by":"crossref","first-page":"301.e17","DOI":"10.1016\/j.urolonc.2021.01.021","article-title":"Prognostic markers in pT3 bladder cancer: a study from the international bladder cancer tissue microarray project","volume":"39","author":"Wang","year":"2021","journal-title":"Urol. Oncol."},{"issue":"15","key":"10.1016\/j.prp.2025.155960_bib9","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13153737","article-title":"Targeting RB1 loss in cancers","volume":"13","author":"Linn","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.prp.2025.155960_bib10","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/s41392-023-01347-1","article-title":"Targeting p53 pathways: mechanisms, structures, and advances in therapy","volume":"8","author":"Wang","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"issue":"6","key":"10.1016\/j.prp.2025.155960_bib11","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/nrc2657","article-title":"p21 in cancer: intricate networks and multiple activities","volume":"9","author":"Abbas","year":"2009","journal-title":"Nat. Rev. Cancer"},{"issue":"8","key":"10.1016\/j.prp.2025.155960_bib12","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11081178","article-title":"p21 in cancer research","volume":"11","author":"Shamloo","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.prp.2025.155960_bib13","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1186\/s12935-021-02396-8","article-title":"p53 signaling in cancer progression and therapy","volume":"21","author":"Marei","year":"2021","journal-title":"Cancer Cell Int."},{"issue":"5","key":"10.1016\/j.prp.2025.155960_bib14","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1111\/cas.14878","article-title":"Therapeutic and prognostic implications of NOTCH and MAPK signaling in bladder cancer","volume":"112","author":"Schulz","year":"2021","journal-title":"Cancer Sci."},{"issue":"8","key":"10.1016\/j.prp.2025.155960_bib15","doi-asserted-by":"crossref","first-page":"530.e9","DOI":"10.1016\/j.urolonc.2019.05.011","article-title":"Prognostic value and association with epithelial-mesenchymal transition and molecular subtypes of the proteoglycan biglycan in advanced bladder cancer","volume":"37","author":"Schulz","year":"2019","journal-title":"Urol. Oncol."},{"issue":"5","key":"10.1016\/j.prp.2025.155960_bib16","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1038\/s41418-022-00988-z","article-title":"Cell cycle regulation: p53-p21-RB signaling","volume":"29","author":"Engeland","year":"2022","journal-title":"Cell Death Differ."},{"issue":"5","key":"10.1016\/j.prp.2025.155960_bib17","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/S0090-4295(01)00968-2","article-title":"p53 in bladder cancer: mechanism of action, prognostic value, and target for therapy","volume":"57","author":"Slaton","year":"2001","journal-title":"Urology"},{"issue":"5","key":"10.1016\/j.prp.2025.155960_bib18","first-page":"4999","article-title":"Clinicopathologic and prognostic significance of p21 (Cip1\/Waf1) expression in bladder cancer","volume":"8","author":"Tang","year":"2015","journal-title":"Int J. Clin. Exp. Pathol."}],"container-title":["Pathology - Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033825001529?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033825001529?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T14:34:44Z","timestamp":1747406084000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0344033825001529"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":18,"alternative-id":["S0344033825001529"],"URL":"https:\/\/doi.org\/10.1016\/j.prp.2025.155960","relation":{},"ISSN":["0344-0338"],"issn-type":[{"value":"0344-0338","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognostic impact of combined loss of RB1, p53 and p21 in muscle-invasive bladder cancer","name":"articletitle","label":"Article Title"},{"value":"Pathology - Research and Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prp.2025.155960","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier GmbH.","name":"copyright","label":"Copyright"}],"article-number":"155960"}}